Oculis Holding Future Growth
Future criteria checks 2/6
Oculis Holding's earnings are forecast to decline at 3.5% per annum while its annual revenue is expected to grow at 59.9% per year. EPS is expected to grow by 7.8% per annum. Return on equity is forecast to be -9.4% in 3 years.
Key information
-3.5%
Earnings growth rate
7.8%
EPS growth rate
| Pharmaceuticals earnings growth | 19.6% |
| Revenue growth rate | 59.9% |
| Future return on equity | -9.4% |
| Analyst coverage | Good |
| Last updated | 04 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 32 | -85 | N/A | N/A | 4 |
| 12/31/2025 | 11 | -69 | N/A | N/A | 7 |
| 12/31/2024 | 1 | -71 | N/A | N/A | 7 |
| 6/30/2024 | 1 | -67 | -52 | -52 | N/A |
| 3/31/2024 | 1 | -59 | -51 | -51 | N/A |
| 12/31/2023 | 1 | -89 | -54 | -54 | N/A |
| 9/30/2023 | 1 | -85 | -49 | -47 | N/A |
| 6/30/2023 | 1 | -78 | -44 | -42 | N/A |
| 3/31/2023 | 1 | -75 | -38 | -35 | N/A |
| 12/31/2022 | 1 | -39 | -29 | -25 | N/A |
| 9/30/2022 | 1 | -35 | -24 | -22 | N/A |
| 12/31/2021 | 1 | -19 | -14 | -14 | N/A |
| 12/31/2020 | 1 | -15 | -12 | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CR5 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CR5 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CR5 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CR5's revenue (59.9% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: CR5's revenue (59.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CR5 is forecast to be unprofitable in 3 years.